A novel vaccine for Aspergillus fumigatus

一种新型烟曲霉疫苗

• 批准号: 6693955
• 负责人: Claude P Selitrennikoff
• 金额: $ 10万
• 依托单位: MYCOLOGICS, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2005-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6693955
• 关键词: Aspergillus; Saccharomyces cerevisiae; biotechnology; cell transformation; drug delivery systems; fungal vaccines; genetic manipulation; laboratory mouse; polymerase chain reaction; recombinant DNA; transfection; transfection /expression vector; vaccine development

DESCRIPTION (provided by applicant): Aspergillus fumigatus is a ubiqutous spore-bearing fungus that causes multiple diseases in humans. These include allergic pulmonary asthma, aspergillomas, and invasive disease of hosts usually with predisposing underlying conditions. For example, in the United States in 1996, there were an estimated 10,190 aspergillosis-related hospitalizations; these resulted in 1970 deaths, 176,300 hospital days, and $633.1 million in costs. The average hospitalization lasted 17.3 days at a cost of about $62,000. Although aspergillosis-related hospitalizations account for a small percentage of hospitalizations in the United States, patients hospitalized with the condition have lengthy hospital stays and high mortality rates. The high mortality rates (in some instances over 90%) are due in part to the lack of rapid and sensitive diagnostics tests (all too often the diagnosis is done post mortem) as well as the lack of effective anti-fungals. Our long-term goal is to develop a safe and effective vaccine against A. fumigatus. In this SBIR Phase I proposal, we will use a novel, proprietary recombinant antigen delivery system and test a number of A. fumigatus proteins as vaccine candidates. We will accomplish this in two specific aims: Specific Aim One: Engineer yeast cells to express each of seven A. fumigatus putative antigens using recombinant DNA technology. Specific Aim Two: Test the in vivo efficacy of each vaccine formulation to protect vaccinated animals against a challenge of A. fumigatus. This work will be a prelude to work in Phase II that will include detailed testing for in vivo efficacy and safety of each vaccine candidate. Ultimately, the Phase I, subsequent Phase II and III research will lead to the development of a vaccine against A. fumigatus.

描述（由申请人提供）：曲曲霉是一种带有多种孢子的真菌，会导致人类多种疾病。这些包括过敏性肺哮喘，曲霉瘤和宿主的侵入性疾病，通常具有易感性的潜在条件。例如，在1996年的美国，估计有10,190次与曲霉相关的住院治疗。这些导致了1970年的死亡，176,300天的死亡和6.331亿美元的费用。平均住院时间持续了17.3天，费用约为62,000美元。尽管与曲霉菌相关的住院治疗占美国住院时间的一小部分，但住院病情的患者却保持了漫长的住院率和高死亡率。高死亡率（在某些情况下超过90％）部分是由于缺乏快速和敏感的诊断测试（验证频率很常，验证是在Mortem完成后进行的）以及缺乏有效的抗灾害。 我们的长期目标是开发针对烟曲霉的安全有效疫苗。在此SBIR I期建议中，我们将使用一种新型的专有重组抗原递送系统，并测试许多烟曲霉蛋白作为候选疫苗。 我们将以两个具体的目标来实现这一目标： 特定目标：工程师酵母细胞使用重组DNA技术表达七个烟曲霉抗原中的每一个。 具体目标两个：测试每种疫苗配方的体内功效，以保护疫苗的动物免受烟曲霉的挑战。 这项工作将是在第二阶段工作的前奏，其中包括针对每个疫苗候选者的体内功效和安全性的详细测试。最终，I期，随后的II期和III期研究将导致针对烟曲霉的疫苗开发。